![Lynn Worth Purkins](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lynn Worth Purkins is the founder of Ziarco Pharma Ltd. which was founded in 2012.
Dr. Purkins held the title of Vice President & Head-Clinical Development at Ziarco Pharma Ltd. from 2012 to 2015.
Dr. Purkins is currently the Vice President-Clinical Operations at Reneo Pharmaceuticals, Inc. since 2018.
Dr. Purkins's former job was as the Head-Clinical Development at Pfizer Ltd. Dr. Purkins holds a doctorate degree from the University of Leeds and an undergraduate degree from Leeds Beckett University.
| Sociétés | Poste | Fin |
|---|---|---|
Pfizer Ltd.
 Pfizer Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines, vaccines & pharmaceutical products | Corporate Officer/Principal | - |
| ONKURE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Ziarco Pharma Ltd.
 Ziarco Pharma Ltd. BiotechnologyHealth Technology Provides therapeutics targeting inflammatory and allergic diseases | Fondateur | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 5 |
|---|---|
University of Leeds
 University of Leeds Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Leeds Beckett University
 Leeds Beckett University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pfizer Ltd.
Pfizer Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines, vaccines & pharmaceutical products | Health Technology |
Ziarco Pharma Ltd.
Ziarco Pharma Ltd. BiotechnologyHealth Technology Provides therapeutics targeting inflammatory and allergic diseases | Health Technology |
Reneo Pharmaceuticals, Inc.
 Reneo Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
